Skip to main content

Table 5 eGFR and dialysis over follow-up by treatment status

From: Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study

  Never Discontinued (n = 51) Discontinueda (n = 42) All Patients (N = 93)
Patients available for eGFR analysisb, n 39 24 63
eGFR prior to first dose of eculizumab in parent study, mL/min/1.73 m2
 Mean (SD) 30.9 (26.9) 29.6 (29.1) 30.4 (27.5)
 Median (range) 24.0 (8.4, 128.3) 12.0 (10.0, 105.5) 22.1 (8.4, 128.3)
eGFR at time of discontinuationc, mL/min/1.73 m2
 Mean (SD) – 92.4 (38.6) –
 Median (range) – 92.3 (34.2, 181.5) –
eGFR at last follow-up, mL/min/1.73 m2
 Mean (SD) 65.2 (33.1) 85.9 (31.8) 73.1 (33.9)
 Median (range) 59.5 (14.8, 152.2) 75.6 (40.0, 153.5) 65.7 (14.8, 153.5)
Patients on dialysis prior to first dose of eculizumab in parent study, n/N (%) 18/51 (35.3) 17/35 (48.6) 35/86 (40.7)
Patients on dialysis at last follow-up, n/N (%) 2/51 (3.9) 5/35 (14.3) 7/86 (8.1)
  1. eGFR estimated glomerular filtration rate; SD standard deviation
  2. aPatients who had eGFR values recorded in the first off-treatment period; includes patients who did and did not reinitiate eculizumab
  3. bExcludes patients on chronic dialysis, defined as lasting for > 90 days without a gap of > 14 days
  4. cDefined as the last eGFR value before the start of the first off-treatment period in the current study
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us